US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
Biocon Biologics recently acquired the global biosimilars business of its long-term partner Viatris
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The company's consolidated revenues for the quarter grew 36% to Rs. 3,020 crore on the back of robust performance across all its three businesses
Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.
Subscribe To Our Newsletter & Stay Updated
